Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of JC-5411-L in advanced prostate cancer with TP53 mutation or AR mutation/amplification
CTR20213314Phase 2Active
- Sponsor
- Wuxi Jesse Pharmaceutical
- Start
- Dec 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of phenethyl isothiocyanate in prostate cancer (PCa), sponsored by Wuxi Jesse Pharmaceutical. Started Dec 2021; status: active.
02
Drugs
phenethyl isothiocyanate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20213314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213314.